Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim™ in Early 2025
22 February 2024 - 1:00AM
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF), also
known as Sirona, is excited to share a new milestone in its
journey. A recent exclusive video interview featuring Dr. Geraldine
Deliencourt-Godefroy, Sirona's Chief Scientific Officer, has been
released by the Investing News Network. In this interview, Dr.
Deliencourt-Godefroy unveils Sirona's ambitious plans to introduce
its innovative anti-aging product, GlycoProteMimTM, to the markets
of North America and Europe in early 2025.
The interview provides an insightful look into
the revolutionary potential of GlycoProteMim in the anti-aging
sector. Viewers can access the full interview on the Investing News
Network’s website through this link:
investingnews.com/sirona-biochem-eyes-2025-launch-of-new-anti-aging-product/
About Sirona Biochem Corp.
Sirona is a cosmetic ingredient and drug
discovery company with proprietary platform technology. Sirona
specializes in stabilizing carbohydrate molecules with the goal of
improving efficacy and safety. New compounds are patented for
maximum revenue potential.
Sirona’s compounds are licensed to leading
companies around the world in return for licensing fees, milestone
fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is
in France and is the recipient of multiple French national
scientific awards and European Union and French government grants.
For more information, please visit www.sironabiochem.com.
For more information regarding this press
release, please contact:
Investor Enquiries:
Christopher Hopton, CFO604.641.4466Email:
Info@sironabiochem.com
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward Looking Statements
This news release includes certain statements
that may be deemed “forward-looking statements”. All statements in
this new release, other than statements of historical facts, that
address events or developments that the Company expects to occur,
are forward-looking statements. Forward-looking statements are
statements that are not historical facts and are generally, but not
always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and
similar expressions, or that events or conditions “will”, “would”,
“may”, “could” or “should” occur. Although the Company believes the
expectations expressed in such forward-looking statements are based
on reasonable assumptions, such statements are not guarantees of
future performance and actual results may differ materially from
those in the forward-looking statements. Factors that could cause
the actual results to differ materially from those in
forward-looking statements include market prices, continued
availability of capital and financing, and general economic, market
or business conditions. Investors are cautioned that any such
statements are not guarantees of future performance and actual
results or developments may differ materially from those projected
in the forward-looking statements. Forward-looking statements are
based on the beliefs, estimates and opinions of the Company’s
management on the date the statements are made. Except as required
by applicable securities laws, the Company undertakes no obligation
to update these forward-looking statements in the event that
management's beliefs, estimates or opinions, or other factors,
should change.
Sirona Biochem (TG:ZSB)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sirona Biochem (TG:ZSB)
Historical Stock Chart
From Oct 2023 to Oct 2024